Clinical Trials Browser

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Salivary Gland Neoplasms, Sarcoma, Thyroid Neoplasms, Colorectal Neoplasms

NCT02477826 2025-10-30

CheckMate 227

Phase 3 Completed

2,747 enrolled 21 charts 2 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02075840 2025-07-25

ALEX

Phase 3 Completed

303 enrolled 31 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03037385 2025-05-31

ARROW

Phase 1/2 Completed

590 enrolled 58 charts 5 FDA

EndocrineGastrointestinalHead & NeckNETThoracic

Thyroid Cancer, Papillary, Adenocarcinoma, Adenocarcinoma, Papillary, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Colorectal Neoplasms, Neuroectodermal Tumors, Carcinoma, Medullary, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 2a

NCT03409614 2025-03-13

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

Phase 3 Completed

790 enrolled 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01828099 2025-01-16

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Phase 3 Completed

376 enrolled 34 charts 1 FDA

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02784171 2024-12-10

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

Phase 2/3 Completed

520 enrolled 16 charts 1 FDA

Other solid neoplasmThoracic

Mesothelioma

NCT02775435 2024-10-08

KEYNOTE-407

Phase 3 Completed

559 enrolled 18 charts 1 FDA

Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02578680 2024-09-20

MK-3475-189

Phase 3 Completed

616 enrolled 19 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01970865 2024-08-12

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Phase 1/2 Completed

364 enrolled 89 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02899299 2024-05-21

CheckMate743

Phase 3 Completed

605 enrolled 17 charts 2 FDA

Other solid neoplasmThoracic

Mesothelioma

NCT02414139 2024-03-20

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

Phase 2 Completed

373 enrolled 34 charts 3 FDA

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT01774721 2023-11-14

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Phase 3 Completed

452 enrolled 35 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT02125461 2023-10-10

PACIFIC

Phase 3 Completed

713 enrolled 23 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02220894 2023-10-10

Keynote 042

Phase 3 Completed

1,274 enrolled 23 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02763579 2023-07-28

IMpower133

Phase 3 Completed

503 enrolled 23 charts 1 FDA

Thoracic

Small Cell Lung Carcinoma

NCT02409342 2023-03-15

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Phase 3 Completed

572 enrolled 32 charts 2 FDA

Thoracic

Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer

NCT01336634 2022-04-04

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Phase 2 Completed

177 enrolled 19 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02737501 2021-08-20

ALTA-1L

Phase 3 Completed

275 enrolled 23 charts 2 FDA

Thoracic

Adenocarcinoma, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms, Carcinoma, Large Cell

NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Phase 1/2 Completed

515 enrolled 28 charts 2 FDA

BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT01121393 2018-12-14

BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

Phase 3 Completed

364 enrolled 28 charts 1 FDA

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT00949650 2018-04-06

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Phase 3 Completed

345 enrolled 23 charts 1 FDA

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung

NCT00525148 2016-09-16

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

Phase 2 Completed

129 enrolled 18 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

PEARLS

Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

FLAURA

CheckMate 816

CheckMate 9LA

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

DESTINY-LUNG02

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

NAVIGATE

CheckMate 227

ALEX

ARROW

Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma

KEYNOTE-407

MK-3475-189

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

CheckMate743

Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

PACIFIC

Keynote 042

IMpower133

A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

ALTA-1L

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations